Baseline and treatment characteristics
| Characteristic . | All patients (N = 475) . | Axi-cel (n = 216) . | Tisa-cel (n = 158) . | Liso-cel (n = 101) . | P value . |
|---|---|---|---|---|---|
| Age at leukapheresis | |||||
| Median (IQR), y | 65 (57-71) | 60 (53-68) | 66 (59-72) | 70 (63-77) | <.0001 |
| ≥65 y, n (%) | 232 (48.8) | 74 (34) | 86 (54) | 72 (71) | <.0001 |
| Male sex, n (%) | 307 (64.6) | 156 (72) | 90 (57) | 61 (60) | .0058 |
| ECOG score 0/1, n (%) | 395 (87.2) | 186 (88) | 137 (88) | 72 (84) | .5606 |
| Disease type, n (%) | |||||
| DLBCL/tFL | 426 (90.1) | 191 (89) | 143 (91) | 92 (91) | .2047 |
| HGBCL | 42 (8.9) | 22 (10) | 13 (8) | 7 (7) | |
| PMBCL | 5 (1.1) | 2 (1) | 1 (1) | 2 (2) | |
| Disease status at referral, n (%) | |||||
| Primary refractory | 125 (28.2) | 79 (37) | 32 (23) | 14 (15) | .0003 |
| Refractory | 164 (36.9) | 75 (36) | 51 (36) | 38 (42) | |
| Relapsed | 155 (34.9) | 57 (27) | 59 (42) | 39 (43) | |
| Previous lines of therapy, n (%) | |||||
| 1 | 16 (3.3) | 0 | 0 | 16 (15.8) | <.0001 |
| 2 | 126 (26.5) | 64 (30) | 31 (20) | 31 (30.7) | |
| >2 | 332 (69.8) | 151 (70) | 127 (80) | 54 (53) | |
| Lymphodepletion, n (%) | |||||
| Fludarabine/cyclophosphamide | 380 (80) | 213 (99) | 92 (58) | 75 (74) | <.0001 |
| Bendamustine | 93 (19.6) | 2 (1) | 65 (41) | 26 (26) | |
| Other/none | 2 (0.4) | 1 (<1) | 1 (1) | 0 | |
| Location of infusion, n (%) | |||||
| Inpatient | 355 (74.7) | 204 (94) | 65 (41) | 86 (85) | <.0001 |
| Outpatient | 120 (25.3) | 12 (6) | 93 (59) | 15 (15) | |
| CRS | |||||
| Incidence, all grade, n (%) | 285 (60) | 172 (79.6) | 64 (10.1) | 49 (48.5) | <.0001 |
| Grade ≥3, incidence, n (%) | 24 (5) | 16 (7) | 5 (3) | 3 (3) | .099 |
| Median days to onset (IQR) | 3 (1-4) | 3 (1-5) | 3 (1-4) | 3 (2-4) | .3792 |
| Median days to resolution (IQR) | 4 (2-6) | 5 (3-7) | 2 (1-4) | 3 (1-4) | <.0001 |
| Onset beyond day 14, n (%) | 0 | 0 | 0 | 0 | ND |
| ICANS | |||||
| Incidence, all grade, n (%) | 154 (32.4) | 112 (51.8) | 16 (10.1) | 26 (25.7) | <.0001 |
| Grade ≥3, incidence, n (%) | 85 (18) | 72 (33) | 3 (2) | 10 (10) | <.0001 |
| Median days to onset (IQR) | 5 (4-7) | 5 (4-7) | 4 (1-7) | 5 (2-8) | .0728 |
| Median days to resolution (IQR) | 5 (2-10) | 6 (3-10) | 3 (2-11) | 3 (0-13) | .1888 |
| Onset beyond day 14, n (%) | 1 (0.7) | 0 | 1 (6) | 0 | ND |
| Tocilizumab use | |||||
| Used at least 1 dose, n (%) | 206 (43.6) | 134 (62) | 41 (26) | 31 (31) | <.0001 |
| Median doses used (IQR) | 1 (1-2) | 2 (1-3) | 1 (1-2) | 1 (1-2) | .0405 |
| Steroids: used at least 1 dose, n (%) | 155 (32.6) | 108 (50) | 16 (10) | 31 (31) | <.0001 |
| Infections: incidence, n (%) | 69 (14.5) | 47 (29) | 22 (16) | 0 | .0050 |
| Mortality | |||||
| All-cause mortality, n (%) | 202 (42.8) | 99 (46) | 76 (48) | 27 (27) | .0011 |
| NRM, n (%) | 45 (9.5) | 25 (12) | 11 (7) | 9 (9) | .3150 |
| Median follow-up, mo (IQR) | 11 (4-19.8) | 13 (5-21) | 11 (5-22) | 6 (3-12) | <.0001 |
| Characteristic . | All patients (N = 475) . | Axi-cel (n = 216) . | Tisa-cel (n = 158) . | Liso-cel (n = 101) . | P value . |
|---|---|---|---|---|---|
| Age at leukapheresis | |||||
| Median (IQR), y | 65 (57-71) | 60 (53-68) | 66 (59-72) | 70 (63-77) | <.0001 |
| ≥65 y, n (%) | 232 (48.8) | 74 (34) | 86 (54) | 72 (71) | <.0001 |
| Male sex, n (%) | 307 (64.6) | 156 (72) | 90 (57) | 61 (60) | .0058 |
| ECOG score 0/1, n (%) | 395 (87.2) | 186 (88) | 137 (88) | 72 (84) | .5606 |
| Disease type, n (%) | |||||
| DLBCL/tFL | 426 (90.1) | 191 (89) | 143 (91) | 92 (91) | .2047 |
| HGBCL | 42 (8.9) | 22 (10) | 13 (8) | 7 (7) | |
| PMBCL | 5 (1.1) | 2 (1) | 1 (1) | 2 (2) | |
| Disease status at referral, n (%) | |||||
| Primary refractory | 125 (28.2) | 79 (37) | 32 (23) | 14 (15) | .0003 |
| Refractory | 164 (36.9) | 75 (36) | 51 (36) | 38 (42) | |
| Relapsed | 155 (34.9) | 57 (27) | 59 (42) | 39 (43) | |
| Previous lines of therapy, n (%) | |||||
| 1 | 16 (3.3) | 0 | 0 | 16 (15.8) | <.0001 |
| 2 | 126 (26.5) | 64 (30) | 31 (20) | 31 (30.7) | |
| >2 | 332 (69.8) | 151 (70) | 127 (80) | 54 (53) | |
| Lymphodepletion, n (%) | |||||
| Fludarabine/cyclophosphamide | 380 (80) | 213 (99) | 92 (58) | 75 (74) | <.0001 |
| Bendamustine | 93 (19.6) | 2 (1) | 65 (41) | 26 (26) | |
| Other/none | 2 (0.4) | 1 (<1) | 1 (1) | 0 | |
| Location of infusion, n (%) | |||||
| Inpatient | 355 (74.7) | 204 (94) | 65 (41) | 86 (85) | <.0001 |
| Outpatient | 120 (25.3) | 12 (6) | 93 (59) | 15 (15) | |
| CRS | |||||
| Incidence, all grade, n (%) | 285 (60) | 172 (79.6) | 64 (10.1) | 49 (48.5) | <.0001 |
| Grade ≥3, incidence, n (%) | 24 (5) | 16 (7) | 5 (3) | 3 (3) | .099 |
| Median days to onset (IQR) | 3 (1-4) | 3 (1-5) | 3 (1-4) | 3 (2-4) | .3792 |
| Median days to resolution (IQR) | 4 (2-6) | 5 (3-7) | 2 (1-4) | 3 (1-4) | <.0001 |
| Onset beyond day 14, n (%) | 0 | 0 | 0 | 0 | ND |
| ICANS | |||||
| Incidence, all grade, n (%) | 154 (32.4) | 112 (51.8) | 16 (10.1) | 26 (25.7) | <.0001 |
| Grade ≥3, incidence, n (%) | 85 (18) | 72 (33) | 3 (2) | 10 (10) | <.0001 |
| Median days to onset (IQR) | 5 (4-7) | 5 (4-7) | 4 (1-7) | 5 (2-8) | .0728 |
| Median days to resolution (IQR) | 5 (2-10) | 6 (3-10) | 3 (2-11) | 3 (0-13) | .1888 |
| Onset beyond day 14, n (%) | 1 (0.7) | 0 | 1 (6) | 0 | ND |
| Tocilizumab use | |||||
| Used at least 1 dose, n (%) | 206 (43.6) | 134 (62) | 41 (26) | 31 (31) | <.0001 |
| Median doses used (IQR) | 1 (1-2) | 2 (1-3) | 1 (1-2) | 1 (1-2) | .0405 |
| Steroids: used at least 1 dose, n (%) | 155 (32.6) | 108 (50) | 16 (10) | 31 (31) | <.0001 |
| Infections: incidence, n (%) | 69 (14.5) | 47 (29) | 22 (16) | 0 | .0050 |
| Mortality | |||||
| All-cause mortality, n (%) | 202 (42.8) | 99 (46) | 76 (48) | 27 (27) | .0011 |
| NRM, n (%) | 45 (9.5) | 25 (12) | 11 (7) | 9 (9) | .3150 |
| Median follow-up, mo (IQR) | 11 (4-19.8) | 13 (5-21) | 11 (5-22) | 6 (3-12) | <.0001 |
DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; HGBL, high-grade B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; tFL, transformed follicular lymphoma. Bolded P values are significant.